SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-047916
Filing Date
2024-02-27
Accepted
2024-02-27 16:07:35
Documents
17
Period of Report
2024-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d802648d8k.htm   iXBRL 8-K 26643
2 EX-99.1 d802648dex991.htm EX-99.1 76289
6 GRAPHIC g802648g0227081338081.jpg GRAPHIC 2222
7 GRAPHIC g802648g0227105128467.jpg GRAPHIC 2767
  Complete submission text file 0001193125-24-047916.txt   248701

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20240227.xsd EX-101.SCH 2889
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20240227_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20240227_pre.xml EX-101.PRE 11287
19 EXTRACTED XBRL INSTANCE DOCUMENT d802648d8k_htm.xml XML 3669
Mailing Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 24686618
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)